CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
APL-130277 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03292016
NCT03292016Phase 2Completed
CompareCT.gov

A Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Sumitomo Pharma America, Inc.·interventional·Posted Sep 25, 2017·Updated Aug 13, 2020

In Brief

A Phase 2 clinical trial evaluating APL-130277, APO-go, and 1 other intervention for Parkinson Disease. Completed, enrolled 8 participants across 3 sites.

Detailed Summary

A study that compares the extent to which apomorphine becomes available in the body after taking either an investigational drug containing apomorphine or apomorphine that is injected under the skin in people with PD complicated by "OFF" episodes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 25, 2017
Enrollment StartAug 22, 2017
Primary CompletionMar 5, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.8 years ago

Interventions

APL-130277drug

APL-130277 sublingual thin film

APO-godrug

Subcutaneous APO-go

Apokyndrug

Subcutaneous APOKYN